CAR-T cell therapy

CAR-T cell therapy collects a patient’s T lymphocytes, engineers them ex vivo with a chimeric antigen receptor (CAR) using a lentiviral or retroviral vector, expands and re-infuses them as a one-time living drug that recognises and kills cancer. It is the flagship advanced therapy medicinal product (ATMP) class, with multiple approved CD19 products (Novartis Kymriah, Kite Yescarta/Tecartus, Bristol Myers Squibb Breyanzi) and BCMA multiple-myeloma products (BMS/2seventy Abecma, Janssen/Legend Carvykti). Kite secured an FDA label update for Yescarta in February 2026, BMS’s Breyanzi monitoring update was approved in Canada in June 2026, Janssen’s Carvykti continues to read out from the LEGEND programme, and Cellectis (France) is advancing off-the-shelf allogeneic CAR-T (UCART) built on its TALEN gene-editing platform.

The key directions of CAR-T cell therapy are:

1. Autologous CD19 CAR-T (CD19 CAR-T): patient-specific CD19-directed CAR-T for B-cell lymphoma and leukemia — Novartis (Kymriah), Kite (Yescarta, Tecartus), Bristol Myers Squibb (Breyanzi).
2. BCMA CAR-T for multiple myeloma (BCMA CAR-T): B-cell-maturation-antigen-directed CAR-T for relapsed myeloma — Bristol Myers Squibb/2seventy (Abecma), Janssen/Legend (Carvykti).
3. Allogeneic off-the-shelf CAR-T (Allogeneic CAR-T): TALEN- or CRISPR-edited donor T cells intended as an immediate, inventory-managed product — Cellectis (UCART).
4. Manufacturing and vein-to-vein access (Manufacturing): apheresis, lentiviral transduction, automated GMP expansion, cryopreservation and lymphodepletion that determine the ~2-4 week vein-to-vein time and scalability.

Sectoral value chain#

[patient T cells (apheresis)] ──> [lentiviral CAR transduction + expansion] ──> [cryopreserved CAR-T product]
                                            │
                                   (lymphodepletion conditioning)
                                            │
                                            ▼
[cancer remission] <─── [CAR-T infusion + CRS/ICANS management] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Lentiviral and retroviral vectors (Lentiviral Vector): all autologous CAR-T products use integrating viral vectors to insert the CAR transgene, and vector supply is a structural manufacturing bottleneck.
• Automated cell processing (Cell Manufacturing): closed systems (e.g. CliniMACS) and single-use bioreactors standardise vein-to-vein time and underpin the CDMO tier.
• Target antigen selection (Target Selection): CD19 (lymphoma/leukemia) and BCMA (myeloma) anchor the approved class, with the allogeneic frontier using gene editing to prevent graft-versus-host and rejection.

The stack pairs CAR transgene design with integrating-vector delivery, closed-system GMP manufacturing, and structured clinical management of the CAR-T unique toxicities.

1. Autologous CD19 CAR-T (CD19 CAR-T):
   • Novartis’s Kymriah was the first approved CAR-T (CD19, pediatric ALL and DLBCL), and Kite’s Yescarta won a February 2026 FDA label update reinforcing its DLBCL lead, with Tecartus extending the franchise.
   • Bristol Myers Squibb’s Breyanzi (CD19) had a monitoring update approved in Canada in June 2026, broadening its clinical use.
2. BCMA CAR-T for myeloma (BCMA CAR-T):
   • Janssen and Legend’s Carvykti (ciltacabtagene autoleucel) and BMS/2seventy’s Abecma (idecabtagene vicleucel) target BCMA in relapsed multiple myeloma, with Carvykti scaling on the LEGEND-2 evidence base.
   • Legend Biotechnology (Nanjing) is the first China-origin CAR-T developer to reach US and EU markets, with Q1 2026 losses narrowing as revenue scaled.
3. Allogeneic off-the-shelf CAR-T (Allogeneic CAR-T):
   • Cellectis uses its TALEN gene-editing platform to build donor-derived UCART products that could be manufactured as inventory, presenting final Phase 1 lasme-cel results in June 2026.
   • Gene editing to knock out the T-cell receptor and HLA is what enables an off-the-shelf product while controlling graft-versus-host and rejection.